000			02077nas a22002537a 4500
003			OSt
005			20210608124531.0
006			m|||||r|||| 00| 0
007			ta
008			171219t2011 sp ||||| |||| 00| 0 spa |
022			_a1477-092X
040			_cSalus Infirmorum
245	0	0	_aAssessing the risk to health care staff from long-term exposure to anticancer drugs – the case of monoclonal antibodies / _cGabriele Halsen, Irene Krämer
500			_aPDF en biblioteca
504			_aBibliografía: p.78-80
520	8		_aToday the occupational health and safety risk involved when handling most anticancer drugs is well recognized and, as a result of regulatory requirements, safety measures have been established. There is little knowledge about the occupational hazard posed by handling monoclonal antibodies assigned to ATC Class L01XC. The aim of our study was to evaluate the occupational risk of monoclonal antibodies. Using the information obtained in a systematic review of the literature, the potentially dangerous properties of the active drug substances were assessed using a specially devised algorithm. As a result, all monoclonal antibodies in question were categorized as substances with developmental toxicity. In addition, gemtuzumab ozogamicin was categorized as mutagenic. In view of the high molecular weights and the proteinogenic nature of monoclonal antibodies, the route of exposure for health care staff is limited to inhalation, unless there is an accident. Employers should implement the necessary administrative and engineering controls. Employees should adhere to the standards in order to avoid occupational exposure. The hazard assessment algorithm devised and the evaluation procedure may also be used for other drugs considered to be dangerous.
653	1	4	_amonoclonal antibodies
653	1	4	_aATC Class L01XC
653	1	4	_aoccupational exposure
653	1	4	_arisk assessment
653	1	4	_aoccupational hazard
773			_g-- 2011, v. 17, 1, p. 68-80 _tJournal of oncology pharmacy practice
942			_2udc _cARTÍCULO
999			_c13184 _d13184